

BEST AVAILABLE COPY

1258642

TO ALL WHOSE THESE PRESENTS SHALL COME:


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 09, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/514,781
FILING DATE: *October 27, 2003*
RELATED PCT APPLICATION NUMBER: PCT/US04/35445

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



Provisional Application Cover Sheet

Address to:
Washington, DC 20231

Express Mail #:
BR5199279285

ER429621378-US

This is a request for filing a PROVISIONAL APPLICATION under 37 C.F.R. § 1.53(b)(2).

Docket Number: Q3351		Type a plus sign (+) inside this box		+
Inventor(s)/Applicant(s)				
Last Name	First Name	Middle Initial	Residence (City and either State or Foreign Country)	
Woo	Y	J	Lafayette Hills, PA	
Title of the Invention (280 Characters Maximum)				
Ethyl Pyruvate Reduces Free Radical Production and Preserves Cardiac Function in a Rat Model of Off-Pump Coronary Bypass				
Correspondence Address				
University of Pennsylvania Center For Technology Transfer 3160 Chestnut Street Suite 200				
City: Philadelphia	State: Pennsylvania	Zip Code: 19104 - 6283	Country: US	
Enclosed Application Parts (check all that apply)				
<input checked="" type="checkbox"/> Specification Number of pages: 10 <input type="checkbox"/> Small Entity Statement				
<input type="checkbox"/> Drawing(s) Number of sheets: <input type="checkbox"/> Other (specify) _____				
Method of Payment (check one)				
<input type="checkbox"/> Our Check No. _____ is enclosed to cover the Provisional filing fees. A duplicate copy of this sheet is enclosed.			Provisional Filing Fee Amount (\$)	\$ 80.00
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 13-2489. A duplicate copy of this sheet is enclosed.				
<input type="checkbox"/> Payment by credit card. Form PTO-2028 is attached.				

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No
 Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

Signature: Y. Joseph Woo
Typed or Printed Name: Y. Joseph Woo

Date: 10/27/03

Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

22151 U.S.PTO
60/514781



102/03

PROVISIONAL APPLICATION SUBMISSION TO USPTO - CONTENTS PAGE

Penn Docket Number : Q3351

First-named Inventor : Woo

Submission Date : October 27, 2003

Prepared by : Andrew Liken

CONTENTS LISTED IN ORDER :

<u>Page Nos.</u>	<u>Descriptor</u>
1	This Page
2-7	MS, "Ethyl ...Bypass", marked pp 1-6, incl. 6 figs
8-10	Abstract for MS above

Total Number of Pages : 10

Q3351 /
RBM

Ethyl Pyruvate Reduces Free Radical Production and Preserves Cardiac Function in a Rat Model Of Off-Pump Coronary Bypass

Matthew D. Taylor MSIII, Todd J. Grand BS, Jeffrey E. Cohen, Vivien Hsu, Suzanne Zentko MD, Mark F. Berry MD, Y. Joseph Woo, MD

University of Pennsylvania School of Medicine,

Dept. of Surgery

American Heart Association Scientific Sessions Nov. 2003

Background

Off-pump coronary artery bypass grafting is associated with transient periods of myocardial ischemia during revascularization. Such ischemia puts the myocardium at risk for contractile dysfunction and injury associated in part by the metabolic depletion of high energy phosphates. In addition, reperfusion following revascularization is associated with myocardial oxidative injury mediated by reactive oxygen species.


Pyruvate, a key glycolytic intermediate, has been shown to be an effective scavenger of hydrogen peroxide and hydroxyl radical.^{1,2} However, its function as an antioxidant is limited by poor stability in aqueous solution.^{3,4} Ethyl pyruvate, a common food additive, has enhanced lipophilic character and in contrast to pyruvate, is very stable in calcium containing aqueous solutions. Previous work utilizing a model of prolonged myocardial ischemia/reperfusion injury demonstrated that ethyl pyruvate enhanced myocardial ATP production, attenuated oxidative injury and infarct size, and preserved cardiac function.⁵ The purpose of this study was to investigate the efficacy of ethyl pyruvate as a myocardial protective agent in a rat model of off-pump coronary artery bypass grafting.

RECEIVED

OCT 27 2003

UNIVERSITY OF PENNSYLVANIA
CENTER FOR TECHNOLOGY TRANSFER

Pyruvate- Glycolytic ATP Generator



- Pyruvate supplementation produces increased NAD⁺
- NAD⁺ is the electron acceptor for reaction 6 producing 1,3-bisphosphoglycerate
- The enzyme, phosphoglycerate kinase, catalyzes reaction 7, in which 1,3-bisphosphoglycerate is converted to 3-phosphoglycerate generating ATP

Source: Biocarta, www.biocarta.com

Methods

Male Wistar rats were anesthetized and mechanically ventilated with a respirator. The right femoral vein was isolated and an intravenous catheter was inserted for administration of treatment solutions. A median sternotomy was performed and the pericardium was reflected exposing the heart. A miniature pressure/volume conductance catheter was inserted into the left ventricular cavity via the apex for hemodynamic measurements. In addition, a flow probe was placed around the ascending aorta to measure cardiac output. (Figure 1) Animals were subjected to transient ischemia via a 10 minute occlusion of the left anterior descending coronary artery followed by 10 minutes of reperfusion. Animals received an IV bolus of Ringer's solution as a control (n=10) or Ringer's ethyl pyruvate (n=10) immediately before the initiation of both ischemia and reperfusion. Hemodynamic parameters were reported as a percentage of baseline measurements. Myocardial ATP levels were determined in the ischemic region following 10 minutes of ischemia (n=10). Myocardial lipid peroxidation, a measure of oxidative stress, was determined in the LV region subjected to ischemia as well as a region not subjected to ischemia as an internal control (n=10).

Figure 1- Photograph of experimental setup for the determination of cardiac function



Results

Myocardial ATP Levels








Figure 2- Myocardial ATP levels determined in the ischemic region following 10 minutes of ischemia (n=5, in both treatment group). Ethyl pyruvate treatment significantly increased ATP levels in ischemic myocardium compared to controls (87.6±29.2 vs. 10.0±2.4 nanomoles/g, *p=0.04).





Conclusion

- In a rat model of off-pump coronary artery bypass utilizing transient myocardial ischemia and reperfusion, ethyl pyruvate enhanced the myocardial energetic state by elevating ATP levels, reduced myocardial oxidative injury, and preserved myocardial function.

References

1. Constantopoulos G and Barranger GA. Nonenzymatic decarboxylation of pyruvate. *Anal Biochem* 1984; 139: 353–358.
2. DeBoer LW, Bekx PA, Han L, Steinke L. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. *Am J Physiol Heart Circ Physiol* 1993; 265: H1571–1576.
3. Montgomery CM, Webb JL. Metabolic studies on heart mitochondria: II. The inhibitory action of parapyruvate on the tricarboxylic acid cycle. *J Biol Chem* 1956; 221: 359–368.
4. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. *Crit Care Med* 2001; 29(8):1513–8.
5. Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. Submitted to *JTCVS* 2003.

Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia.

Y. Joseph Woo, MD ¹
Matthew D. Taylor, BS ¹
Jeffrey E. Cohen ¹
Vasant Jayasankar, MD ¹
Lawrence T. Bish, BS ²
Jeffrey Burdick BS ¹
Timothy J. Pirolli ²
Mark F. Berry, MD ¹
Vivian Hsu ¹
Todd Grand, BS ¹

University of Pennsylvania School of Medicine
Departments of Surgery ¹ and Physiology ²

Corresponding Author:

Y. Joseph Woo, M.D.
Assistant Professor of Surgery
Director, Minimally Invasive and Robotic Cardiac Surgery Program
Division of Cardiothoracic Surgery
Department of Surgery
University of Pennsylvania
Silverstein 4
3400 Spruce St
Philadelphia PA 19104

215-662-2956
215-349-5798 FAX
wooy@uphs.upenn.edu

Presented at the 83rd Annual Meeting of the American Association for Thoracic Surgery,
Boston MA, May 5, 2003.

Abstract

Objective: Myocardial injury and dysfunction following ischemia are mediated in part by reactive oxygen species. Pyruvate, a key glycolytic intermediary, is an effective free radical scavenger, but unfortunately, is limited by aqueous instability. The ester derivative, ethyl pyruvate, is stable in solution and should function as an antioxidant and energy precursor. This study sought to evaluate ethyl pyruvate as a myocardial protective agent in a rat model of ischemia/reperfusion injury.

Methods: Rats underwent 30minute ischemia and 30minute reperfusion of the left anterior descending coronary artery territory. Immediately prior to both ischemia and reperfusion, animals received an intravenous bolus of either ethyl pyruvate (n=26) or vehicle control(n=26). Myocardial high energy phosphate levels were determined by ATP assay, oxidative injury was measured by lipid peroxidation assay, infarct size was quantified by triphenyltetrazolium chloride staining and cardiac function was assessed in vivo.

Results: Ethyl pyruvate administration significantly increased myocardial ATP levels compared to control, 87.6 ± 29.2 nanomoles/g vs. 10.0 ± 2.4 nanomoles/g, $p=0.03$. In ischemic myocardium, ethyl pyruvate reduced oxidative injury compared to control: 63.8 ± 3.3 nmol/g vs. 89.5 ± 3.0 nmol/g, $p<0.001$. Ethyl pyruvate diminished infarct size as a percentage of area at risk: $25.3 \pm 1.5\%$ vs. $33.6 \pm 2.1\%$, $p=0.005$. Ethyl pyruvate improved myocardial function compared to controls: Max Pressure 86.6 ± 2.9 mmHg vs. 73.5 ± 2.5 mmHg, $p<0.001$, Max dP/dt 3518 ± 243 mmHg/sec vs. 2703 ± 175 mmHg/sec, $p=0.005$, dV/dt 3097 ± 479 μl/sec vs. 2120 ± 287 μl/sec, $p=0.04$, Ejection Fraction $41.9 \pm 3.8\%$ vs. $31.4 \pm 4.1\%$, $p=0.03$, Cardiac Output 26.7 ± 0.9 ml/min vs. 22.7 ± 1.3 ml/min,

p=0.01, and End systolic pressure volume relationship slope $1.08 \pm$ vs. $0.59 \pm$, p=0.02.

Conclusions: In this study of myocardial ischemia reperfusion injury, ethyl pyruvate enhanced myocardial ATP levels, attenuated myocardial oxidative injury, decreased infarct size, and preserved cardiac function.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/035445

International filing date: 27 October 2004 (27.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/514,781
Filing date: 27 October 2003 (27.10.2003)

Date of receipt at the International Bureau: 17 December 2004 (17.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.